Loading company
$1.94-6.7%Nov 13 close
Next earnings: December 11, 2026
Figures through June 30, 2026, from the 10-Q filed August 13, 2026
Past performance
- 1W
- -9.3%
- 1M
- -27.3%
- 3M
- -63.7%
- 6M
- -85.1%
- 1Y
- +11.2%
- 5Y
- -96.1%
$1.94-6.7%Nov 13 close
Next earnings: December 11, 2026
Figures through June 30, 2026, from the 10-Q filed August 13, 2026
Edesa Biotech, Inc. is scheduled to report next on December 11, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending September 30, 2021, against the same quarter a year earlier.
| Measure | 3 months toSep 30, 2021 | 3 months toSep 30, 2020 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $500.00 | -100.00% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Edesa Biotech, Inc. has no earnings call transcript available.
“Our third quarter marked an important operational inflection point for Edesa, with the completion of preparations for our Phase 2 vitiligo study keeping us on track for initial enrollment in the coming weeks,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Edesa Biotech, Inc. (Nasdaq: EDSA) is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Its clinical pipeline is focused on two therapeutic areas: Medical Dermatology and Respiratory. In Medical Dermatology, Edesa is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase 3-ready asset developed for use as a potential therapy for moderate-to-severe chronic Allergic
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Edesa Biotech, Inc.’s Item 2.02 8-K filed August 13, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.